Role of Hematopoietic Stem Cell Transplant in the Management of

Section editor George P. Canellos has disclosed no financial relationships relevant to the content of this article. The article discusses unlabeled, investigational, or alternative use(s) of a product, device, or technique—alemtuzumab (Campath; Genzyme), rituximab (Rituxan; Genentech), iodine-131 tositumomab (Bexxar; Corixa Corporation and GlaxoSmithKline), yttrium-90 ibritumomab tiuxetan (Zevalin; Spectrum Pharmaceuticals, Inc.)—for conditioning regimens for HSCT. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. LEARNING OBJECTIVES 1. Evaluate recent data regarding outcomes of autologous and allogeneic stem cell transplant for follicular lymphoma. 2. Apply patient and disease characteristics to predict favorable post-transplant outcomes for patients with follicular lymphoma. 3. Enumerate the indications for referral of patients with follicular lymphoma to a transplant center. 4. Compare the advantages and disadvantages of allogeneic versus autologous stem cell transplant for follicular lymphoma. This article is available for continuing medical education credit at CME.TheOncologist.com.CM